Guardant Health's Total Assets for the quarter that ended in Mar. 2022 was $2,129.6 Mil.
Warning Sign:
If a company builds asset at 107.2% a year, faster than its revenue growth rate of 56.7% over the past 5 years, it means that the company may be getting less efficent.
During the past 12 months, Guardant Health's average Total Assets Growth Rate was 187.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 96.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 107.20% per year.
During the past 6 years, Guardant Health's highest 3-Year average Total Assets Growth Rate was 174.30%. The lowest was 57.70%. And the median was 96.20%.
Total Assets is connected with ROA %. Guardant Health's annualizedROA % for the quarter that ended in Mar. 2022 was -22.75%. Total Assets is also linked to Revenue through Asset Turnover. Guardant Health's Asset Turnover for the quarter that ended in Mar. 2022 was 0.04.
Guardant Health Total Assets Historical Data
The historical data trend for Guardant Health's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Guardant Health Annual Data
Trend
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Total Assets
342.94
587.40
962.54
2,271.78
2,204.50
Guardant Health Quarterly Data
Dec16
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Total Assets
2,346.74
2,291.89
2,225.53
2,204.50
2,129.60
Guardant Health Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Guardant Health's Total Assets for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Net Income data used here is four times the quarterly (Mar. 2022) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Guardant Health's Asset Turnover for the quarter that ended in Mar. 2022 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Guardant Health Total Assets Related Terms
Thank you for viewing the detailed overview of Guardant Health's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
1.7(4.04%) Volume: 1,361,483 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:GH has been successfully added to your 
